Author

Mark Krogh Hvistendahl

SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 METABOLIC BALANCE TRIAL
SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 METABOLIC BALANCE TRIAL

Mark Krogh Hvistendahl  et al.

TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS
TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS

Mark Krogh Hvistendahl  et al.

SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE: A DOUBLE-BLIND, CROSSOVER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL
SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE: A DOUBLE-BLIND, CROSSOVER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL

Mark Krogh Hvistendahl  et al.

GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOGUE, EXPOSURE DOES NOT CORRELATE WITH HEPATIC INDOCYANINE GREEN CLEARANCE
GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOGUE, EXPOSURE DOES NOT CORRELATE WITH HEPATIC INDOCYANINE GREEN CLEARANCE

Mark Krogh Hvistendahl  et al.

Item 1 - 4 / 4
1